Skip to content
Sonic
AI
Sonic
AI
Home
Discover
Ask Sonic
Projects
Use with Claude or ChatGPT
Show me around
Request source or feature
Gilead Sciences CEO Daniel O'Day at Semafor World Economy, Sonic AI
Home
/
Semafor World Economy Summit 2026
/
Gilead Sciences CEO Daniel O'Day at Semafor World Economy
Semafor World Economy Summit 2026
Notify me
•
May 1, 2026
•
13:47
Conference
Interview
Gilead Sciences CEO Daniel O'Day at Semafor World Economy
From
Semafor World Economy Summit 2026
· 2026
Daniel O'Day
(CEO, Gilead Sciences, guest)
Get the full transcript next time Semafor World Economy Summit 2026 releases an episode
Summary, key quotes, top claims, and the searchable transcript — emailed automatically. No card needed.
Sign up
Executive Summary
Gilead is aggressively scaling access to its revolutionary twice-yearly HIV prevention drug, lenacapivir, in sub-Saharan Africa through a no-profit, voluntary licensing model with partners like PEPFAR and the Global Fund.
The company is strategically diversifying beyond its core virology focus, making acquisitions in oncology and autoimmune diseases to build a robust pipeline in areas like cell therapy and antibody-drug conjugates.
Gilead is integrating artificial intelligence to accelerate drug discovery, aiming to reduce the typical decade-long process to six to eight years, thereby increasing the pace of innovation.
The company is actively engaging in US healthcare policy debates, advocating for reforms that lower patient out-of-pocket costs by addressing inefficiencies in the supply chain, where intermediaries capture 50% of every dollar spent on medicine.
Continue your research
Keep pulling the thread on Daniel O'Day.
Global Health Equity and Access
Strategic Diversification into Oncology and Immunology
8
quotes
Transcript
Key Arguments
Analysis
Quotes & Entities
8
Related
Loading transcript...
Processed May 10, 2026
Daily intelligence brief →
yt-dlp + mlx-whisper + Gemini